title: Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia.
abstract: ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL(T315I) mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that "switch-control" inhibitors block BCR-ABL(T315I) activity by preventing ABL from switching from the inactive to active conformation.
authors.affiliation: Division of Tumour Biology, The Institute of Cancer Research, London, UK.
authors.forename: Leisl
authors.initials: L
authors.lastname: Packer
authors.forename: Richard
authors.initials: R
authors.lastname: Marais